Skip to main content

Vomiting clinical trials at UCSF

1 research study open to eligible people

Vomiting is when you throw up, or your stomach expels its contents. UCSF is examining the effectiveness of a drug, Olanzapine, to control vomiting in children receiving high-intensity chemotherapy. This trial is aimed at mitigating the unpleasant side effects of cancer treatment.

Showing trials for
  • RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

    open to eligible people ages 30 months to 18 years

    Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

    San Francisco, California and other locations

Our lead scientists for Vomiting research studies include .

Last updated: